"Farnesol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A colorless liquid extracted from oils of plants such as citronella, neroli, cyclamen, and tuberose. It is an intermediate step in the biological synthesis of cholesterol from mevalonic acid in vertebrates. It has a delicate odor and is used in perfumery. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
| Descriptor ID |
D005204
|
| MeSH Number(s) |
D02.033.415.400 D02.455.849.765.424 D10.289.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Farnesol".
Below are MeSH descriptors whose meaning is more specific than "Farnesol".
This graph shows the total number of publications written about "Farnesol" by people in this website by year, and whether "Farnesol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Farnesol" by people in Profiles.
-
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies. Clin Lymphoma Myeloma Leuk. 2015 Jul; 15(7):433-438.e2.
-
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer. Invest New Drugs. 2012 Dec; 30(6):2391-9.
-
Farnesol decreases biofilms of Staphylococcus epidermidis and exhibits synergy with nafcillin and vancomycin. Pediatr Res. 2011 Dec; 70(6):578-83.
-
Salirasib in the treatment of pancreatic cancer. Future Oncol. 2010 Jun; 6(6):885-91.
-
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010 Jan; 65(2):235-41.
-
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol. 2007 Aug-Sep; 106(1-5):102-10.
-
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer. 2005 Dec 10; 117(5):746-54.
-
Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice. J Mol Med (Berl). 1999 Nov; 77(11):792-7.
-
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line. Oncogene. 1999 Jul 15; 18(28):4120-30.
-
Physiological role of HMG-CoA reductase in regulating egg production by Schistosoma mansoni. Am J Physiol. 1989 Sep; 257(3 Pt 2):R618-25.